spiroindolones potent compound class treatment malaria
recent reports increased tolerance artemisinin derivatives-the recently adopted class antimalarials-have prompted need new treatments spirotetrahydro-beta-carbolines spiroindolones potent drugs kill blood stages plasmodium falciparum plasmodium vivax clinical isolates low nanomolar concentration spiroindolones rapidly inhibit protein synthesis p falciparum effect ablated parasites bearing nonsynonymous mutations gene encoding p-type cation-transporter atpase4 pfatp4 optimized spiroindolone nitd609 shows pharmacokinetic properties compatible once-daily oral dosing single-dose efficacy rodent malaria model
